144 related articles for article (PubMed ID: 35220228)
21. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
[TBL] [Abstract][Full Text] [Related]
22. Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult.
Zhao X; Chen M; Qi X; Zhu H; Yang G; Guo Y; Dong Q; Yang Q
Front Endocrinol (Lausanne); 2021; 12():805194. PubMed ID: 35154006
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant external beam radiotherapy for locally invasive papillary thyroid cancer.
Megwalu UC; Orloff LA; Ma Y
Head Neck; 2019 Jun; 41(6):1719-1724. PubMed ID: 30620424
[TBL] [Abstract][Full Text] [Related]
24. Risk of second primary thyroid cancer in cancer survivors.
Yuan Y; Sun P; Xiao H; Li L; Li J; Ai X
Sci Rep; 2024 May; 14(1):12478. PubMed ID: 38816510
[TBL] [Abstract][Full Text] [Related]
25. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.
Bhojani N; Capitanio U; Suardi N; Jeldres C; Isbarn H; Shariat SF; Graefen M; Arjane P; Duclos A; Lattouf JB; Saad F; Valiquette L; Montorsi F; Perrotte P; Karakiewicz PI
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):342-8. PubMed ID: 20117287
[TBL] [Abstract][Full Text] [Related]
26. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
27. A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations.
Brown AP; Neeley ES; Werner T; Soisson AP; Burt RW; Gaffney DK
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):127-35. PubMed ID: 19910129
[TBL] [Abstract][Full Text] [Related]
28. Risk of thyroid malignancy following an index head and neck squamous cell carcinoma: A population-based study.
Chan JY; Gooi Z; Mydlarz WK; Agrawal N
Ear Nose Throat J; 2016 Dec; 95(12):E7-E11. PubMed ID: 27929600
[TBL] [Abstract][Full Text] [Related]
29. Non-Small Cell Lung Cancer as a Second Primary Among Patients With Previous Malignancy: Who Is at Risk?
Wu GX; Nelson RA; Kim JY; Raz DJ
Clin Lung Cancer; 2017 Sep; 18(5):543-550.e3. PubMed ID: 28412093
[TBL] [Abstract][Full Text] [Related]
30. Exposure to radiotherapy for first primary cancer as a risk factor for second primary thyroid cancer: A case-control study.
Cuellar Cuellar AA; Cuellar Rivera DI; Fierro-Maya LF; Posso Valencia H
Ann Endocrinol (Paris); 2020 Dec; 81(6):539-544. PubMed ID: 33290749
[TBL] [Abstract][Full Text] [Related]
31. Use of external beam radiotherapy is associated with reduced incidence of second primary head and neck cancer: a SEER database analysis.
Rusthoven K; Chen C; Raben D; Kavanagh B
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):192-8. PubMed ID: 18078720
[TBL] [Abstract][Full Text] [Related]
32. Cancer incidence after localized therapy for prostate cancer.
Moon K; Stukenborg GJ; Keim J; Theodorescu D
Cancer; 2006 Sep; 107(5):991-8. PubMed ID: 16878323
[TBL] [Abstract][Full Text] [Related]
33. Dual malignancies in the setting of differentiated thyroid carcinoma: their synchronous or metachronous nature, impact of radioiodine treatment on occurrence of second malignancy and other associated variables.
Gandhi S; Abhyankar A; Basu S
Nucl Med Commun; 2014 Feb; 35(2):205-9. PubMed ID: 24217429
[TBL] [Abstract][Full Text] [Related]
34. Radiation treatment of patients with primary pediatric malignancies: risk of developing thyroid cancer as a secondary malignancy.
Rose J; Wertheim BC; Guerrero MA
Am J Surg; 2012 Dec; 204(6):881-6; discussion 886-7. PubMed ID: 23026382
[TBL] [Abstract][Full Text] [Related]
35. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
36. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea.
Cho YY; Lim J; Oh CM; Ryu J; Jung KW; Chung JH; Won YJ; Kim SW
Cancer; 2015 Jan; 121(2):259-68. PubMed ID: 25223713
[TBL] [Abstract][Full Text] [Related]
37. Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer.
Guo X; Liu M; Hou H; Liu S; Zhang X; Zhang Y; Wu P; Pang C; Wang J
Int J Clin Oncol; 2019 Aug; 24(8):957-965. PubMed ID: 30903422
[TBL] [Abstract][Full Text] [Related]
38. Association of colorectal cancer and prostate cancer and impact of radiation therapy.
Huo D; Hetzel JT; Roy H; Rubin DT
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):1979-85. PubMed ID: 19531678
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of adjuvant external beam radiotherapy for papillary thyroid cancer based on competitive risk model and propensity score matching.
Zhou J; Wu C; Fan S; Zhao M
Sci Rep; 2023 Apr; 13(1):6925. PubMed ID: 37117278
[TBL] [Abstract][Full Text] [Related]
40. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer.
Zelefsky MJ; Housman DM; Pei X; Alicikus Z; Magsanoc JM; Dauer LT; St Germain J; Yamada Y; Kollmeier M; Cox B; Zhang Z
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):953-9. PubMed ID: 22172904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
